Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]
Phase 1 trial results of NT-I7 after CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma show early efficacy signal…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
A Phase 3 trial comparing Loncastuximab Tesirine plus Rituximab to standard immunochemotherapy in relapsed or refractory diffuse large B-cel…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating CC-486 (oral azacitidine) added to standard therapy in older adults with newly diagnosed diffuse large B…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD22 CAR T cells in pediatric and young adult patients with recurrent or refractory CD22-expressing B-cell mal…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma [EARLY_Phase 1]
Early-phase clinical trial update on the safety, efficacy and metabolic kinetics of CT1182 injection in relapsed/refractory non-Hodgkin lymp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]
Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; …
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. [Phase 2]
A Phase 2 clinical trial is evaluating CAR-T cell therapy combined with autologous stem cell transplantation for high-risk relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL [Phase 2]
A Phase 2 trial is evaluating serplulimab, chidamide, and rituximab followed by sequential R-CHOP in newly diagnosed elderly patients with M…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL [Phase 1, Phase 2]
Phase I/II clinical trial update describing the study of Rapcabtagene Autoleucel in chronic lymphocytic leukemia, small lymphocytic lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL [Phase 1]
This Clinical Trials update describes a Phase 1 study evaluating external beam radiotherapy followed by a bispecific antibody therapy for re…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 study of polatuzumab vedotin with the R-GDP regimen in relapsed/refractory diffuse large B-cell lymphoma was terminated, with result…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) [Phase 1, Phase 2]
Substudy 01A of MK-9999-01A (LIGHTBEAM-U01) evaluates Zilovertamab Vedotin in pediatric and young adult participants with hematologic malign…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL [Phase 3]
A Phase 3 trial evaluating tucidinostat in combination with R-CHOP for newly diagnosed double-expressor diffuse large B-cell lymphoma has co…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial update on subcutaneous epcoritamab, with or without lenalidomide, as first-line therapy for diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
A Phase 3 study evaluating subcutaneously injected epcoritamab plus oral lenalidomide versus intravenous rituximab with gemcitabine and oxal…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]
This document reports on a Phase 3 trial of epcoritamab versus investigator's choice chemotherapy in relapsed/refractory diffuse large B-cel…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL [Phase 1]
This document summarizes a completed Phase 1 trial evaluating OPB-111077 in combination with bendamustine and rituximab for relapsed or refr…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas [Phase 1]
Phase 1 trial evaluating the safety and tolerability of a multi-agent regimen including ibrutinib, rituximab, etoposide, prednisone, vincris…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission [Phase 2]
Phase 2 clinical trial evaluating chidamide maintenance in MRD-positive double-expressor diffuse large B-cell lymphoma patients in first com…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies [Phase 1]
Phase 1 dosimetry and biodistribution study of the radiotracer [18F]-Fludarabine in untreated lymphoid malignancies, including chronic lymph…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial of tazemetostat plus venetoclax for relapsed/refractory non-Hodgkin lymphoma has been terminated, including diffuse l…